西达本胺联合依西美坦治疗绝经后晚期激素受体阳性乳腺癌(ACE):一项随机、双盲、安慰剂对照的3期试验
ACE试验在22个中国肿瘤中心纳入365例绝经后晚期激素受体阳性/HER2阴性乳腺癌患者,按2:1随机接受西达本胺或安慰剂联合依西美坦。西达本胺组研究者评估中位无进展生存期为7.4个月,安慰剂组为3.8个月(HR 0.75,95%CI 0.58-0.98;p=0.033)。3-4级血液学不良事件在西达本胺组更常见。
要点
- 西达本胺联合依西美坦较安慰剂联合依西美坦改善无进展生存期(HR 0.75)。
- 中性粒细胞减少、血小板减少和白细胞减少等3-4级血液学不良事件在西达本胺组更常见。
- 西达本胺联合依西美坦可能成为经内分泌治疗后进展的此类患者的新治疗选择。
核心结论
- 在既往内分泌治疗后进展的晚期激素受体阳性/HER2阴性乳腺癌患者中,西达本胺联合依西美坦较安慰剂联合依西美坦改善无进展生存期。
- 3-4级血液学不良事件在西达本胺联合依西美坦组较安慰剂联合依西美坦组更常见。
- 西达本胺联合依西美坦可能成为这些患者的新治疗选择。
研究设计与样本
- 随机、双盲、安慰剂对照的3期ACE试验,在中国22个专科肿瘤中心进行。
- 纳入365例绝经后激素受体阳性/HER2阴性晚期乳腺癌患者,按2:1随机分配至西达本胺组244例或安慰剂组121例。
- 西达本胺30 mg口服每周两次或安慰剂,所有患者同时口服依西美坦25 mg每日一次;随机化按有无内脏转移分层。
- 主要终点为研究者评估的无进展生存期;疗效分析基于全分析集,安全性分析基于至少接受一次研究药物且有至少一份安全性病例报告表的患者。
主要发现
- 中位随访时间13.9个月(IQR 9.8-17.5)。
- 研究者评估的中位无进展生存期:西达本胺组7.4个月(95%CI 5.5-9.2)vs 安慰剂组3.8个月(95%CI 3.7-5.5),HR 0.75(95%CI 0.58-0.98;p=0.033)。
- 最常见的3或4级不良事件:中性粒细胞减少西达本胺组124/244例(51%)vs 安慰剂组3/121例(2%),血小板减少67/244例(27%)vs 3/121例(2%),白细胞减少46/244例(19%)vs 3/121例(2%)。
- 任何原因的严重不良事件:西达本胺组51/244例(21%)vs 安慰剂组7/121例(6%)。
- 未报告治疗相关死亡。
关键数值与推荐
- 入组条件:绝经后女性(≥60岁,或<60岁但血清卵泡刺激素和雌二醇浓度在绝经后范围),激素受体阳性/HER2阴性乳腺癌,在至少一种内分泌治疗(晚期/转移或辅助)后复发或进展,至少一个可测量病灶,ECOG体能状态0-1,器官功能及血液学生化参数达标。
- 随机化前最近一次治疗后复发或进展为必要条件,但内分泌治疗不必是随机化前最近一次治疗。
- 西达本胺30 mg口服每周两次联合依西美坦25 mg口服每日一次。
临床怎么用
- 原文未据此给出推荐。
- 作者认为西达本胺联合依西美坦可能成为经既往内分泌治疗后进展的晚期激素受体阳性/HER2阴性乳腺癌患者的新治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tucidinostat (formerly known as chidamide) is an oral subtype-selective histone deacetylase inhibitor. In an exploratory study, the combination of tucidinostat with exemestane showed preliminary signs of encouraging anti-tumour activity in patients with advanced hormone receptor-positive breast cancer. To build on these findings, we aimed to assess the efficacy and safety of this combination in a randomised trial in a larger population of postmenopausal patients with advanced, hormone receptor-positive breast cancer. METHODS: We did the randomised, double-blind, placebo-controlled, phase 3 ACE trial at 22 specialist cancer centres in China. Eligible patients were postmenopausal women (aged ≥60 years or aged <60 years if their serum follicle-stimulating hormone and oestradiol concentrations were within postmenopausal ranges) with hormone receptor-positive, HER2-negative breast cancer, whose disease had relapsed or progressed after at least one endocrine therapy (either in advanced or metastatic or adjuvant setting), and who had at least one measurable lesion, adequate organ function, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and adequate haematological and biochemical parameters. Endocrine therapy did not have to be the most recent therapy before randomisation, but recurrence or progression after the most recent therapy was a prerequisite. Patients were randomly assigned (2:1) by a dynamic randomisation scheme via an interactive web-response system to receive 30 mg oral tucidinostat or placebo twice weekly. All patients in both groups also received 25 mg oral exemestane daily. Randomisation was stratified according to the presence of visceral metastases (yes vs no). Patients, investigators, study site staff, and the sponsor were masked to treatment assignment. The primary endpoint was investigator-assessed progression-free survival. Efficacy analyses were done in the full analysis set population, comprising all patients who received at least one dose of any study treatment, and safety analyses were done in all patients who received at least one dose of any study treatment and for whom at least one safety case report form was available. This study is registered with ClinicalTrials.gov, number NCT02482753. The study has reached the required number of events for final analysis of the primary endpoint. The trial is no longer enrolling patients, but follow-up for investigation of overall survival is ongoing. FINDINGS: Between July 20, 2015, and June 26, 2017, 365 patients were enrolled and randomly assigned, 244 to the tucidinostat group and 121 to the placebo group. The median duration of follow-up was 13·9 months (IQR 9·8-17·5). Investigator-assessed median progression-free survival was 7·4 months (95% CI 5·5-9·2) in the tucidinostat group and 3·8 months (3·7-5·5) in the placebo group (HR 0·75 [95% CI 0·58-0·98]; p=0·033). The most common grade 3 or 4 adverse events in either group were neutropenia (124 [51%] of 244 patients in the tucidinostat group vs three [2%] of 121 patients in the placebo group), thrombocytopenia (67 [27%] vs three [2%]), and leucopenia (46 [19%] vs three [2%]). Serious adverse events of any cause occurred in 51 (21%) of 244 patients in the tucidinostat group and seven (6%) of 121 patients in the placebo group. No treatment-related deaths were reported. INTERPRETATION: Tucidinostat plus exemestane improved progression-free survival compared with placebo plus exemestane in patients with advanced, hormone receptor-positive, HER2-negative breast cancer that progressed after previous endocrine therapy. Grade 3-4 haematological adverse events were more common in the tucidinostat plus exemestane group than in the placebo plus exemestane group. Tucidinostat plus exemestane could represent a new treatment option for these patients. FUNDING: Chipscreen Biosciences.
引用
- Jiang Z, Li W, Hu X, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019. PMID: 31036468. doi:10.1016/S1470-2045(19)30164-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。